Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2019 Feb 19;7(4):544–551. doi: 10.1158/2326-6066.CIR-18-0444

Figure 4. Blockade of CXCR2 ameliorates carcinogenesis in exGF mice.

Figure 4.

A, Gross view of colonic tumors in AOM/DSS-treated SPF (n=16; 8 males and 8 females) and exGF mice (n=15; 8 males and 7 females) injected with control antibody (IgG) or a CXCR2 neutralizing antibody (500 μg twice a week; SPF/cont IgG, n=8; SPF/aCXCR2, n=8; exGF/cont IgG, n-8; exGF/aCXCR2, n=7). B, Total tumor surface area and C, tumor surface area per tumor in the colon at day 80 after initiation of the AOM/DSS regimen (day 122 of life). D, total tumor number was quantified using a dissecting microscope. E, Spleen weight and colon length from each experimental group were determined. F, Each dot represents the frequency of the indicated MDSC subpopulation (G-MDSC: CD11b+Ly6Ghigh; M-MDSC: CD11b+Ly6Chigh) in the colonic mucosa from individual mice in the indicated groups. One-way ANOVA and Tukey’s Multiple Comparison Test was used to determine significance. Data are from one experiment showing the means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.